Clinical Trials Directory

Trials / Conditions / Locally Advanced Urothelial Carcinoma

Locally Advanced Urothelial Carcinoma

21 registered clinical trials studyying Locally Advanced Urothelial Carcinoma — 6 currently recruiting.

StatusTrialSponsorPhase
RecruitingDual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
NCT07492628
Beijing BiotechPhase 1
WithdrawnN-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
NCT07217496
Vadim S KoshkinPhase 1
RecruitingA Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Tr
NCT06524544
National Cancer Institute (NCI)Phase 3
RecruitingConsolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
NCT07048457
Yale UniversityPhase 2
Active Not RecruitingA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and With
NCT06483334
Merck Sharp & Dohme LLCPhase 1 / Phase 2
RecruitingComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected
NCT06265285
Mayo ClinicPhase 2
Active Not RecruitingEnfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
NCT05923190
Fox Chase Cancer CenterPhase 2
Active Not RecruitingSafety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors
NCT05544552
Tyra Biosciences, IncPhase 1 / Phase 2
Active Not RecruitingTesting Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemo
NCT04963153
National Cancer Institute (NCI)Phase 1
Active Not RecruitingTrying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594
Alliance for Clinical Trials in OncologyPhase 3
RecruitingPersonalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli
NCT05269381
Mayo ClinicPhase 1 / Phase 2
Active Not RecruitingTremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
NCT05154994
University of UtahPhase 1
TerminatedBiomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
NCT05052372
xCures—
Active Not RecruitingARID1A and/or KDM6A Mutation and CXCL13 Expression
NCT04953104
M.D. Anderson Cancer CenterPhase 2
RecruitingCabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
NCT04878029
Emory UniversityPhase 1
Active Not RecruitingImmune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
NCT04848519
Emory UniversityPhase 2
TerminatedSelinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced
NCT04856189
Mamta ParikhPhase 1 / Phase 2
Active Not RecruitingSonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
NCT04007744
Mayo ClinicPhase 1
Active Not RecruitingTesting the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelia
NCT03854474
National Cancer Institute (NCI)Phase 1 / Phase 2
Active Not RecruitingTesting MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advance
NCT03244384
National Cancer Institute (NCI)Phase 3
Active Not RecruitingEribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney
NCT00365157
National Cancer Institute (NCI)Phase 1 / Phase 2